Company: RCUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001724521-25-000101
Chunk: 245

Company: Arcus Biosciences, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 245
---
 - anti-CD39In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under this arrangement. As of June 30, 2025, we may incur additional clinical and regulatory milestone payments of up to $14 million and royalty payments in the low single digits on net sales of the licensed products under this agreement. We did not have any milestones or royalties due under this arrangement for the three and six months ended June 30, 2025 and 2024. Abmuno LicenseIn 2016, we entered into an agreement (the "Abmuno Agreement") with Abmuno Therapeutics LLC ("Abmuno"), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. As of June 30, 2025, under this arrangement we may incur additional clinical, regulatory and commercialization milestone payments of up to $88 million.We did not have any milestones due under this arrangement for the three and six months ended June 30, 2025 and 2024.

Note 5. Revenues 

The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):Three Months Ended June 30,Six Months Ended June 30,Over timePoint in time2025202420252024Gilead collaboration      License and R&D services* $154 $27 $177 $160 Access rights* 6 9 11 17 Taiho collaboration      Other*— 3 — 7 Total revenues  $160 $39 $188 $184 Total revenues from collaborations$152 $28 $172 $163 Total revenues from a customer$8 $11 $16 $21 Revenues from Gilead accounted for 100% and 92% of Total revenues for the three months ended June 30, 2025 and 2024, respectively and 100% and 96% of Total revenues for the six months ended June 30, 2025 and 2024, respectively.

11

The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):Three Months Ended June 30,Six Months Ended June 30,202520242